Literature DB >> 2442504

Microvascular mechanisms involved in calcium antagonist edema formation.

D Gustafsson.   

Abstract

The effects of calcium antagonists on microcirculation in cat skeletal muscle were studied using a plethysmographic technique. Nifedipine given locally intraarterially decreased vascular resistance in a dose-dependent way by means of vasodilatation that was relatively more pronounced in precapillary vessels than in postcapillary vessels. This led to an increase in capillary hydrostatic pressure, which was the main force for the concomitant transcapillary fluid filtration from blood to tissue. Capillary filtration coefficient, which reflects precapillary sphincter tone (and thus the capillary surface area available for fluid exchange) and specific capillary permeability, was not changed much by nifedipine, even when vasodilatation was pronounced. A comparison of five different calcium antagonists (diltiazem, felodipine, nifedipine, nimodipine, and verapamil) showed that at the same degree of vasodilatation these agents caused the same increase in capillary hydrostatic pressure and the same net transcapillary fluid transfer, but caused no change in capillary filtration coefficient. Nifedipine also interfered with local vascular control in the tissue, leading to an impairment of "autoregulation of capillary hydrostatic pressure" at variations in arterial blood pressure and an impairment of protection against increased hydrostatic load in dependent vascular beds. It is concluded that peripheral edema (usually ankle edema) during treatment with calcium antagonists may result from vasodilatation alone and an inhibition of local vascular (myogenic) control.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442504     DOI: 10.1097/00005344-198710001-00023

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  23 in total

1.  Effects of thiopental on resistance vessels in cat skeletal muscle.

Authors:  P O Grände; D Gustafsson; L Lindberg
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 2.  Ankle oedema and sympathetic activation.

Authors:  Roberto Fogari
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Treatment of resistant hypertension.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

4.  Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40-80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5-10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies.

Authors:  Steen Neldam; Colin Edwards; Margreet Lang; Russell Jones
Journal:  Curr Ther Res Clin Exp       Date:  2012-02

Review 5.  Aspects on the benefit-risk balance of felodipine in hypertension.

Authors:  D Elmfeldt; S Westerling
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 6.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

7.  An evaluation of a potential calcium channel blocker-lower-extremity edema-loop diuretic prescribing cascade.

Authors:  Scott Martin Vouri; Joseph S van Tuyl; Margaret A Olsen; Hong Xian; Mario Schootman
Journal:  J Am Pharm Assoc (2003)       Date:  2018-07-20

Review 8.  Management of calcium channel antagonist overdose.

Authors:  Steven D Salhanick; Michael W Shannon
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 9.  Individualizing antihypertensive combination therapies: clinical and hemodynamic considerations.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

10.  Felodipine in the treatment of patients with severe hypertension and impaired renal function.

Authors:  R Larsson; M K Lindsjö; B Danielsson; U Bengtsson; J H Hardlund; P A Sjöström; D Elmfeldt; L Moberg
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.